Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque
Article Abstract:
Development of therapeutic agents for severe acute respiratory syndrome (SARS) viral infection using short interfering RNA (siRNA) inhibitors exemplifies a powerful new means to combat emerging infectious diseases. Potent siRNA inhibitors of severe acute respiratory syndrome (SARS) coronavirus (SCV) in vitro are further evaluated for efficacy and safety in a rhesus macaque.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Good ACE, bad ACE do battle in lung injury, SARS
Article Abstract:
Angiotensin-converting enzyme 2 (ACE2) is useful for protection against lung injury caused by severe acute respiratory syndrome coronavirus (SARS-CoV). The conversion of angiotensin II to angiotensin 1-7 by ACE2 reduces angiotensin II binding to the cell membrane receptors angiotensin II type 1a receptor (AT1aR) and angiotensin II type 2 receptor (AT2R).
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Initiation of antiretroviral therapy during recent HIV-1 infection results in lower residual viral reservoirs
- Abstracts: Vaccines: Past, present and future. Vaccines in the public eye. T cell vaccines for microbial infections
- Abstracts: Physician-assisted suicide: A legitimate medical practice? Meeting the survival needs of the world's least healthy people
- Abstracts: Massive congenital intracranial teratoma with skull rupture at delivery
- Abstracts: Mental health research emerges from hurricane ruin. Scientists stumped by dual push for open access, secrecy. Race-based heart drug might stall search for better markers